Pfizer’s Prevenar 13 was found to be maintaining its overwhelming 70% share in the pneumococcal vaccine market.

According to its distribution & shipment performance data, sales of Prevenar 13 in 1H this year reached ₩19.4 billion, and its annual sales are expected to exceed that of the ₩38.1 made last year.

In terms of growth, the growth of its competitor, MSD’s Prodiax 23, is slightly ahead. The product’s 1H sales were ₩8.5 billion, and if it maintains the status quo, its gross sales will exceed that of the ₩14.8 billion it had made in 2021.

To strengthen its capabilities, Pfizer joined forces with Chong Kun Dang, one of the strongest